MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of marketable...
$201,250K
Net cash provided by
(used in) investing...
$109,372K
Canceled cashflow
$91,878K
Net increase
(decrease) in cash, cash...
-$26,283K
Canceled cashflow
$109,372K
Stock-based compensation
$11,706K
Right-of-use assets and lease
liabilities, net
$2,909K
Depreciation expense
$2,866K
Non-cash interest
expense related to loan...
$462K
Issuance of common stock
under employee stock...
$264K
Purchases of marketable
securities
$87,471K
Purchases of property and
equipment
$4,407K
Net cash used in
operating activities
-$135,319K
Canceled cashflow
$17,943K
Net cash provided by
(used in) financing...
-$336K
Canceled cashflow
$264K
Net loss
-$129,766K
Deferred revenue
-$10,325K
Accrued expense and
other liabilities
-$7,226K
Accounts payable
-$3,011K
Accretion of marketable
securities
-$2,409K
Prepaid expenses and
other assets
$525K
Cash paid for debt
issuance costs
$400K
Cash paid for
financing costs
$200K
Back
Back
Cash Flow
source: myfinsight.com
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)